Holen Sie sich die Stockscreener-App
0.79
0.13%
0.001
Handel nachbörslich:
.79
Schlusskurs vom Vortag:
$0.789
Offen:
$0.7922
24-Stunden-Volumen:
21,884
Relative Volume:
0.34
Marktkapitalisierung:
$34.99M
Einnahmen:
$15.97M
Nettoeinkommen (Verlust:
$-24.40M
KGV:
-1.0415
EPS:
-0.7585
Netto-Cashflow:
$-45.82M
1W Leistung:
-9.02%
1M Leistung:
-8.58%
6M Leistung:
-24.76%
1J Leistung:
-11.26%
1-Tages-Spanne:
$0.79
$0.81
1-Wochen-Bereich:
$0.789
$0.8999
52-Wochen-Spanne:
$0.50
$1.385
Elutia Inc Stock (ELUT) Company Profile
Firmenname
Elutia Inc
Sektor
Branche
Telefon
240-247-1143
Adresse
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
0.79 | 36.31M | 15.97M | -24.40M | -45.82M | -0.7585 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-02 | Eingeleitet | Cowen | Outperform |
| 2020-11-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-11-02 | Eingeleitet | Truist | Buy |
Elutia Inc Aktie (ELUT) Neueste Nachrichten
Elutia CFO Matthew Ferguson Executes 12,500 Options and Forfeits Shares in Insider Deal - Kalkine Media
ELUT: Drug-eluting biomatrix targets surgical infections, with strong demand and full funding to launch - TradingView
Elutia at H.C. Wainwright conference: capital, data and launch path By Investing.com - Investing.com India
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th - marketscreener.com
Elutia will discuss how to address infections after reconstructive surgery - Stock Titan
Elutia Inc. (NASDAQ: ELUT) Share Price, ELUT Stock News, ELUT Share Price & Updates - kalkine.com.au
Elutia to Participate in the Lake Street Capital Markets - GlobeNewswire
Post-surgical infections will be discussed at Elutia's upcoming talks - Stock Titan
Elutia (ELUT) Holds Steady at $0.88 as Shares Consolidate Between Support and ResistanceOpening Range Breakout - careplusvn.com
Elutia Inc. Earnings Call Highlights Funding, NXT Outlook - TipRanks
Elutia (ELUT) Move: Moves 2.32% Lower to $0.90; Price Levels: Traders Can Monitor the $0.85-$0.95 Range under the Current SnapshotSwing Entry Signals - vinanet.vn
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
Cellution Biologics Acquires SimpliDerm From Elutia for Up to $11 Million - citybiz
ELUT Looks 5.6% Overvalued on GF Value™ - GuruFocus
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. - The Manila Times
Elutia Flat on Sale to Cellution - Baystreet.ca
Elutia sells SimpliDerm business for up to $11 million - Investing.com
Elutia sells SimpliDerm business for up to $11 million By Investing.com - Investing.com India
Elutia gets $8 million at closing as FDA clearance is expected in 2027 - Stock Titan
SILVERARC CAPITAL MANAGEMENT, LLC Trims Elutia Inc (ELUT) Stake -- Shares Look 11% Overvalued on GF Value - GuruFocus
Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. - marketscreener.com
Elutia (ELUT) Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Advance 1.49%Earnings Outlook Update - vinanet.vn
Elutia Inc (ELUT) Stock News Today - TradingKey
Elutia Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-08-16 - Seeking Alpha
Downgrade: What You Need To Know About The Latest Elutia Inc. (NASDAQ:ELUT) Forecasts - simplywall.st
Elutia secures $26M to launch NXT-41x, targetin... - Pluang
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results - Sahm
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com Australia
Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares - Stock Titan
Elutia Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic - GuruFocus
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ... By GuruFocus - Investing.com Canada
ELUT Looks 2.2% Undervalued on GF Value™ Amid Challenging Sales and Cash Flow - GuruFocus
Earnings call transcript: Elutia Q2 2026 revenue miss offset by margin gains - Investing.com Nigeria
ELUT: Q2 delivered improved margins, strong funding, and high surgeon demand for NXT-41x - TradingView
Elutia secures $26M in capital, expects FDA decision on NXT-41 - Investing.com Australia
Elutia Q2 2026 Earnings Call Transcript - Benzinga
ELUT: Improved margins, strong funding, and high surgeon demand set up NXT-41x for 2028 launch - TradingView
Elutia Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Elutia Inc. Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41X Launch in $1.5 Billion Plastic and Reconstructive Surgery Market - marketscreener.com
Elutia secures $15 million financing for product development By Investing.com - Investing.com Nigeria
Elutia Inc. (ELUT) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Is Elutia Inc (ELUT) Positioned for Growth After Q2 Earnings? EPS at -$0.15, Revenue at $2.90M -- GF Score: 34/100 - GuruFocus
Elutia Secures $15 Million Loan Financing From Avenue Capital Group - TradingView
Elutia secures $15 million financing for product development - Investing.com
Elutia Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Elutia 2Q Sales $2.43M >ELUT - Moomoo
Elutia's Biomatrix Targets 15–20% Infection Rates in Plastic Surgery - Stock Titan
Finanzdaten der Elutia Inc-Aktie (ELUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Elutia Inc-Aktie (ELUT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| NEELS GUIDO J | Director |
Jan 30 '26 |
Buy |
1.04 |
20,000 |
20,800 |
118,750 |
| NEELS GUIDO J | Director |
Jan 29 '26 |
Buy |
1.06 |
15,000 |
15,900 |
98,750 |
| NEELS GUIDO J | Director |
Jan 28 '26 |
Buy |
1.06 |
15,000 |
15,900 |
83,750 |
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):